- Conditions
- Dravet Syndrome
- Interventions
- stiripentol
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 11 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Dravet Syndrome, Epileptic Encephalopathies Associated With SCN1A Mutations
- Interventions
- Stiripentol
- Drug
- Lead sponsor
- Cook Children's Health Care System
- Other
- Eligibility
- 6 Months to 18 Years
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Dravet Syndrome
- Interventions
- Stiripentol
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 6 Months and older
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
- Interventions
- Fenfluramine, Placebo
- Drug
- Lead sponsor
- Zogenix, Inc.
- Industry
- Eligibility
- 1 Year to 35 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Dravet Syndrome
- Interventions
- Retrospective study
- Other
- Lead sponsor
- Biocodex
- Industry
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Dravet Syndrome
- Interventions
- ZX008 (Fenfluramine Hydrochloride), Matching Placebo
- Drug
- Lead sponsor
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- San Francisco, California • Aurora, Colorado • Chicago, Illinois + 2 more
- Conditions
- Dravet Syndrome (DS), Children Under 2 Years
- Interventions
- fenfluramine
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 12 Months to 24 Months
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Dravet Syndrome
- Interventions
- Stiripentol
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 1 Year to 21 Years
- U.S. locations
- 1
- States / cities
- Aurora, Colorado